Pharma in Pakistan: Margins, Growth, and the Real Investment Story

Let me walk you through what's actually happening in Pakistan's pharmaceutical sector — and why the usual metrics might be misleading you. The story isn't as simple as "growing population equals growing demand." In fact, there's a deeper twist around margins, pricing, and how you should evaluate pharma stocks.

The Demand Myth: Population Isn't Everything

You've probably heard that pharma has never been in shortage of demand in Pakistan. The population is growing, so obviously the need for medicines is growing too, right? And that's partly true — but here's the catch: the purchase power hasn't been matching that growth. When you actually look at buying behaviour, the purchase was not that good. Yes, the population grows, but that doesn't automatically translate into robust sales.

So while the narrative of "ever-growing demand" sounds compelling, the reality on the ground is that consumers are struggling to buy even the basics. That's a critical distinction to keep in mind.

The Real Driver: Margins, Not Just Volume

What actually makes pharma attractive in Pakistan? It's the margins. The profit per unit on multivitamins and various other medicines is what has historically drawn companies and investors. But again, high margins don't mean much if the purchase volume doesn't follow. You can have a fantastic gross margin on paper, but if people aren't buying, your top line crawls.

That leads me to a key point: many investors talk about operating leverage — the idea that once a company's fixed costs are covered, every extra rupee of revenue drops straight to profit. But in this environment, with weak purchase traction, operating leverage might not kick in the way you'd hope.

Why PE Ratio and Earnings Growth Can Fool You

Here's something I've seen people get wrong repeatedly. They look at a pharma stock and say, "Oh, the PE multiple is low, so it's cheap." Or they see a good earnings growth percentage and assume it's a great investment. But I never bet on those numbers alone — and neither should you.

A low PE without understanding the quality of earnings is meaningless. And earnings growth that's driven by price hikes rather than real volume growth? That's not sustainable. The lesson is simple: earnings growth is only a good investment when the growth comes from solid fundamentals, not from accounting tricks or one-off regulatory benefits.

Government Deregulation